Comments
Loading...
Ultragenyx Pharmaceutical Stock Guidance | NASDAQ:RARE | Benzinga
Ultragenyx Pharmaceutical issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/13/2025 | RARE | Ultragenyx Pharmaceutical | FY | 2025 | — | — | — | $640.00M | $670.00M | $651.93M | Get Alert |
| 01/12/2025 | RARE | Ultragenyx Pharmaceutical | FY | 2024 | — | — | — | $555.00M | $560.00M | $541.43M | Get Alert |
| 01/12/2025 | RARE | Ultragenyx Pharmaceutical | FY | 2025 | — | — | — | $640.00M | $670.00M | $638.35M | Get Alert |
| 11/05/2024 | RARE | Ultragenyx Pharmaceutical | FY | 2024 | — | — | — | $530.00M | $550.00M | $536.80M | Get Alert |
| 08/01/2024 | RARE | Ultragenyx Pharmaceutical | FY | 2024 | — | — | — | $530.00M | $550.00M | $513.16M | Get Alert |
| 05/02/2024 | RARE | Ultragenyx Pharmaceutical | FY | 2024 | — | — | — | $500.00M | $530.00M | $513.00M | Get Alert |
| 02/15/2024 | RARE | Ultragenyx Pharmaceutical | FY | 2024 | — | — | — | $500.00M | $530.00M | $504.31M | Get Alert |
| 01/08/2024 | RARE | Ultragenyx Pharmaceutical | FY | 2023 | — | — | — | $430.00M | $435.00M | $436.11M | Get Alert |
| 01/08/2024 | RARE | Ultragenyx Pharmaceutical | FY | 2024 | — | — | — | $500.00M | $530.00M | $523.86M | Get Alert |
| 11/02/2023 | RARE | Ultragenyx Pharmaceutical | FY | 2023 | — | — | — | $425.00M | $450.00M | $438.74M | Get Alert |
| 10/16/2023 | RARE | Ultragenyx Pharmaceutical | Q3 | 2023 | — | — | — | $96.00M | $100.00M | $113.33M | Get Alert |
| 08/03/2023 | RARE | Ultragenyx Pharmaceutical | FY | 2023 | — | — | — | $425.00M | $450.00M | $437.55M | Get Alert |
| 05/04/2023 | RARE | Ultragenyx Pharmaceutical | FY | 2023 | — | — | — | $425.00M | $450.00M | $435.57M | Get Alert |
| 02/16/2023 | RARE | Ultragenyx Pharmaceutical | FY | 2023 | — | — | — | $425.00M | $450.00M | $432.78M | Get Alert |
FAQ
What is the most recent guidance for Ultragenyx Pharmaceutical (RARE)?
There have been no specific sales or earnings guidance reported for Ultragenyx Pharmaceutical in recent months.
Browse guidance and forecast on all stocks.